首页> 美国卫生研究院文献>ClinicoEconomics and Outcomes Research: CEOR >Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

【2h】

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

机译：从Atlas-M试验数据开始对在意大利接受基于Atazanavir的三联疗法的HIV阳性患者简化为Atazanavir + ritonavir +拉米夫定双重疗法的预算影响分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThis analysis aimed at evaluating the impact of a therapeutic strategy of treatment simplification of atazanavir (ATV)+ ritonavir (r) + lamivudine (3TC) in virologically suppressed patients receiving ATV+r+2 nucleoside reverse transcriptase inhibitors (NRTIs) on the budget of the Italian National Health Service (NHS).

机译：背景本分析旨在评估简化的阿扎那韦（ATV）+利托那韦（r）+拉米夫定（3TC）的治疗策略对接受ATV + r + 2核苷逆转录酶抑制剂（NRTIs）病毒学抑制的患者的影响。意大利国家卫生局（NHS）。

著录项

期刊名称 ClinicoEconomics and Outcomes Research: CEOR
作者
Umberto Restelli; Massimiliano Fabbiani; Simona Di Giambenedetto; Carmela Nappi; Davide Croce;
展开▼
作者单位

展开▼
年(卷),期 2017(9),-1
年度 2017
页码 173–179
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
protease inhibitor economic evaluation cost de-intensification antiretroviral therapy Italian National Health Service;

机译：蛋白酶抑制剂;经济评估;成本;去强化;抗逆转录病毒疗法;意大利国家卫生局;

相似文献

外文文献

1. Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [J] . Umberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, ClinicoEconomics and Outcomes Research . 2017,第6期

机译：从Atlas-M试验数据开始，对意大利接受基于Atazanavir的三联疗法的HIV阳性患者简化为Atazanavir +利托那韦+拉米夫定双重疗法的预算影响分析的更新
2. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [J] . Umberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, ClinicoEconomics and Outcomes Research . 2017,第10期

机译：从Atlas-M试验数据开始，对在意大利接受基于Atazanavir的三联疗法的HIV阳性患者简化为Atazanavir + ritonavir +拉米夫定双重疗法的预算影响分析
3. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum] [J] . ClinicoEconomics and Outcomes Research . 2017,第3期

机译：从Atlas-M试验的数据开始，对意大利接受基于Atazanavir的三联疗法的HIV阳性患者简化为Atazanavir + ritonavir +拉米夫定双重疗法的预算影响分析[更正]
4. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial Corrigendum [O] . 2017

机译：从Atlas-M试验的数据开始对意大利接受基于atazanavir的三联疗法的HIV阳性患者简化为atazanavir + ritonavir +拉米夫定双重疗法的预算影响分析更正
5. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial Corrigendum [O] . Umberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, 2017

机译：ATAZANAVIR + Ritonavir + Lamivivine患者的简化预算影响分析艾滋病毒阳性患者的艾滋病毒阳性患者从地图集为基于ATAZANAVIR的三重疗法开始从ATLAS-M试验数据勘误

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

摘要

著录项

相似文献

相关主题

期刊订阅